Protalix (PLX) Shares Jump Following FDA Approval of ELELYSO, Co. to Host Call at 8am ET Wednesday
Tweet Send to a FriendGet Alerts PFE Hot Sheet
Price: $29.04 -0.24%
EPS Growth %: -6.9%
Financial Fact:
Net income attributable to Pfizer Inc.: 2.75B
Today's EPS Names:
ANF, DXLG, FL, More
EPS Growth %: -6.9%
Financial Fact:
Net income attributable to Pfizer Inc.: 2.75B
Today's EPS Names:
ANF, DXLG, FL, More
Trade PFE Now!
Pfizer Inc. (NYSE: PFE) and Protalix BioTherapeutics, Inc. (AMEX: PLX) announced today that the US FDA approved ELELYSO™ (taliglucerase alfa) for injection, an enzyme replacement therapy (ERT) for the long-term treatment of adults with a confirmed diagnosis of type 1 Gaucher disease.
Protalix said it will host a conference call and webcast for Wednesday, May 2, 2012 at 8:00 AM EDT to review the U.S. Food and Drug Administration's approval of ELELYSO™ for the treatment of Type 1 Gaucher disease.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Protalix said it will host a conference call and webcast for Wednesday, May 2, 2012 at 8:00 AM EDT to review the U.S. Food and Drug Administration's approval of ELELYSO™ for the treatment of Type 1 Gaucher disease.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Merck (MRK) Says Efficacy Not Achieved in Preladenant Phase 3s; Will Discontinue
- Biogen Idec (BIIB) Appoints Spyros Artavanis-Tsakonas as CSO
- Cardiovascular Systems (CSII) ORBIT II Trial Met Endpoints
Create E-mail Alert Related Categories
Conference Calls, Corporate News, FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
